References

1. Hamilton-Craig I, Kostner KM, Woodhouse S, Colquhoun D: Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations. Int J Evid Based Healthc. 2012 Sep;10(3):181-90. doi: 10.1111/j.1744-1609.2012.00275.x. [PubMed:22925614 ]
2. Lageder H: [Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia]. Wien Klin Wochenschr. 1980 Feb 1;92(3):95-101. [PubMed:6985560 ]
3. McCullough PA, Ahmed AB, Zughaib MT, Glanz ED, Di Loreto MJ: Treatment of hypertriglyceridemia with fibric acid derivatives: impact on lipid subfractions and translation into a reduction in cardiovascular events. Rev Cardiovasc Med. 2011;12(4):173-85. doi: 10.3909/ricm0619. [PubMed:22249508 ]
4. Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D: Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant. 2000 Dec;15(12):1993-9. [PubMed:11096145 ]
5. Dierkes J, Westphal S, Luley C: Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet. 1999 Jul 17;354(9174):219-20. [PubMed:10421307 ]
6. Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesaniemi YA, Gebski VJ, Scott RS, Keech AC: Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia. 2011 Feb;54(2):280-90. doi: 10.1007/s00125-010-1951-1. Epub 2010 Nov 4. [PubMed:21052978 ]